NCT00504634View on ClinicalTrials.gov

Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

May 31, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

1 mg/m\^2 IV On Days 1, 4, 8, and 11.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00504634 - Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma | Biotech Hunter | Biotech Hunter